Literature DB >> 20591499

Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis.

José María Pelayo-Terán1, Rocío Pérez-Iglesias, Javier Vázquez-Bourgon, Ignacio Mata, Eugenio Carrasco-Marín, José Luis Vázquez-Barquero, Benedicto Crespo-Facorro.   

Abstract

Genetic factors play an important role in the understanding of clinical response to antipsychotic treatments. We aimed to assess the effect of the catechol-O-methyltransferase (COMT) genotype in the short-term (6 weeks) clinical response of 161 first-episode psychosis patients. COMT genotype was not related to clinical response at 6 weeks. Val homozygote patients showed higher negative symptoms than Met homozygote patients. The COMT Val158 genotype seems to be related to the severity of negative symptoms rather than to clinical response.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20591499     DOI： 10.1016/j.psychres.2010.06.006

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN： 0165-1781            Impact factor:   3.222


  12 in total

Review 1.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 2.  Neurobiological background of negative symptoms.

Authors:  Silvana Galderisi; Eleonora Merlotti; Armida Mucci
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

3.  Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population.

Authors:  Wen Jun Li; Chang Gui Kou; Yaqin Yu; Shilong Sun; Xuan Zhang; Thomas R Kosten; Xiang Yang Zhang
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-02-21       Impact factor: 3.568

Review 4.  The promise of biological markers for treatment response in first-episode psychosis: a systematic review.

Authors:  Guillaume Fond; Marc-Antoine d'Albis; Stéphane Jamain; Ryad Tamouza; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Markus Leweke; Shôn Lewis; Phillip McGuire; Andreas Meyer-Lindenberg; Iris E Sommer; Inge Winter-van Rossum; Shitij Kapur; René S Kahn; Dan Rujescu; Marion Leboyer
Journal:  Schizophr Bull       Date:  2015-03-10       Impact factor: 9.306

5.  Treatment Response in First-episode Schizophrenia.

Authors:  Rebecca Schennach; Michael Riedel; Richard Musil; Hans-Jürgen Möller
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

6.  Effort-related decision making in humanized COMT mice: Effects of Val158Met polymorphisms and possible implications for negative symptoms in humans.

Authors:  Jen-Hau Yang; Rose E Presby; Suzanne Cayer; Renee A Rotolo; Peter A Perrino; R Holly Fitch; Merce Correa; Elissa J Chesler; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2020-06-25       Impact factor: 3.697

Review 7.  Theranostic Biomarkers for Schizophrenia.

Authors:  Matea Nikolac Perkovic; Gordana Nedic Erjavec; Dubravka Svob Strac; Suzana Uzun; Oliver Kozumplik; Nela Pivac
Journal:  Int J Mol Sci       Date:  2017-03-30       Impact factor: 5.923

8.  Monoamine oxidase a and B gene polymorphisms and negative and positive symptoms in schizophrenia.

Authors:  Beatriz Camarena; Ana Fresán; Alejandro Aguilar; Raúl Escamilla; Ricardo Saracco; Jorge Palacios; Alfonso Tovilla; Humberto Nicolini
Journal:  ISRN Psychiatry       Date:  2012-04-19

Review 9.  Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis.

Authors:  Eric Huang; Clement C Zai; Amanda Lisoway; Malgorzata Maciukiewicz; Daniel Felsky; Arun K Tiwari; Jeffrey R Bishop; Masashi Ikeda; Patricio Molero; Felipe Ortuno; Stefano Porcelli; Jerzy Samochowiec; Pawel Mierzejewski; Shugui Gao; Benedicto Crespo-Facorro; José M Pelayo-Terán; Harpreet Kaur; Ritushree Kukreti; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Daniel J Müller; James L Kennedy
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-29       Impact factor: 5.176

Review 10.  Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.

Authors:  Seenae Eum; Adam M Lee; Jeffrey R Bishop
Journal:  Dialogues Clin Neurosci       Date:  2016-09       Impact factor: 5.986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.